Video

Current Treatment Landscape for HER2+ Breast Cancer

Author(s):

Ruth O'Regan, MD, University of Rochester Medical CenterJoyce O'Shaugnessy, MD, Texas Oncology

Breast cancer experts discuss the evolution of HER2-targeted treatments, including margetuximab, trastuzumab, tucatinib, and neratinib, along with unmet needs in patients with HER2+ breast cancer.

Related Videos
VK Gadi, MD, PhD
Ana Christina Garrido-Castro, MD
Julia Foldi, MD, PhD
Julia Foldi, MD, PhD
Kevin Kalinsky, MD, MS
A panel of 3 experts on breast cancer
A panel of 3 experts on breast cancer
Julia Foldi, MD, PhD
A panel of 3 experts on breast cancer
Related Content
Erin Frances Cobain, MD
June 8th 2024

MammaPrint High 2 Indication Could Be Predictive Biomarker for Immunotherapy in HR+/HER2– Early Breast Cancer

Stephen Liu, MD; Sara A. Hurvitz, MD, FACP; S. Vincent Rajkumar, MD; Sumanta Kumar Pal, MD, FASCO; Shubham Pant, MD, MBBS
May 23rd 2024

Oncology Experts Preview Top Abstracts From the 2024 ASCO Annual Meeting

Erika Hamilton, MD, of Sarah Cannon Research Institute
June 5th 2024

Second-Line T-DXd Data Remain Strong in HER2+ Metastatic Breast Cancer

OncLive On Air
March 18th 2024

Revisit the OncLive On Air Episodes From February 2024

Shengfeng Li
June 3rd 2024

Bevacizumab Biosimilar Avzivi Receives Positive CHMP Opinion

Giuseppe Curigliano, MD, PhD
June 2nd 2024

Trastuzumab Deruxtecan Prolongs PFS in Pretreated HR+, HER2-Low and -Ultralow Metastatic Breast Cancer